Sun Pharmaceutical Industries Limited

This study investigates whether clascoterone cream 1%, an FDA-approved acne medication, works by reducing sebum (skin oil) production. Researchers will measure forehead oil levels and changes in skin bacteria in 40 participants aged 12 and older with mild to moderate acne. The go…

This study tested the acne cream Winlevi in 10 people with darker skin tones (Fitzpatrick types IV, V, VI). The goal was to see how well it cleared or nearly cleared acne after 16 weeks. Acne is very common, but there is little research focused on skin of color, so this study hel…

This phase 3 trial tested a single injection of tildrakizumab against placebo in 508 adults with active psoriatic arthritis who had previously used anti-TNF drugs. The main goal was to see if more people achieved at least a 20% improvement in joint symptoms. The study is now comp…

This Phase 2 trial tested an experimental oral drug called SCD-044 in 250 adults with moderate to severe atopic dermatitis (eczema). Participants received one of three doses of SCD-044 or a placebo for 16 weeks. The main goal was to see if the drug could reduce eczema severity by…

This study tested a combination of two acne treatments—Winlevi (a hormone-blocking cream) and adapalene 0.3% gel—to see how well they work together in real-life use. Twenty people with acne used both treatments for 16 weeks. The main goal was to see how many achieved clear or alm…

This Phase 3 study tested the drug tildrakizumab in 99 adults with moderate to severe nail psoriasis. Participants received either the drug or a placebo for 28 weeks to see if it improved nail appearance and reduced pain. The trial is complete, and results may help determine if t…

This study tested an experimental drug called SCD-044 in 263 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo to see if it could improve skin symptoms like redness and scaling. The main goal was to measure how many people achieve…

This completed study looked at the long-term safety of the drug sonidegib in 323 adults with a type of skin cancer called locally advanced basal cell carcinoma. Participants took a daily 200 mg pill, and researchers tracked side effects, serious events, and deaths. The goal was t…